doi:10.1001/jama.2023.24945 [8] Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trial
Diabetes Metab Res Rev 32:776790 Rosenstock J, Reusch J, Bush M et al (2009) Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing
5 Stars are not enough to express the amazing and life changing work that Rachel does
A.MarxJ
Dietary supplements should not be used as a substitute for a balanced, varied diet and a healthy lifestyle
Do not inject into muscle tissue intentionally, as intramuscular injection of semaglutide is not approved and creates significantly faster, less controlled absorption